Compare Exelon Corporation Common Stock (EXC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelon Corporation Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Exelon Corporation Common Stock trades at $42.82 (market cap $43.61B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Exelon Corporation Common Stock is far larger — about 8.9× Travere Therapeutics Inc. Common Stock's market cap, and Exelon Corporation Common Stock pays a 3.97% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| EXC | TVTX | |
|---|---|---|
Market Cap | $43.61B | $4.88B |
Volume | 5,642,975 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $50.29 | $67.52 |
52-Week Low | $40.20 | $26.79 |
Enterprise Value | $94.47B | $5.01B |
Dividend Yield | 3.97% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Exelon (EXC) trades at $42.34, up 0.52% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong earnings beats in recent quarters except for a Q2 2026 miss, with Q3 2026 results expected on October 30, 2026. Financials show solid profitability with a 10.99% net income margin and a P/E of 15.56, while cash flow trends indicate improving operational performance.
The outlook is cautiously optimistic, supported by a $48.11 analyst consensus price target and institutional accumulation, but risks include regulatory approvals for dividends and high RSI levels suggesting overbought conditions. Earnings growth and grid investment plans are key catalysts, though investor sentiment remains divided amid rate environment uncertainties.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Exelon Corporation Common Stock
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
